AcelRx Q1 2023 Earnings Report
Key Takeaways
AcelRx Pharmaceuticals reported a net loss attributable to common shareholders of $8.2 million, or $0.75 per basic and diluted share, for the first quarter of 2023. The company closed the divestment of DSUVIA to Alora Pharmaceuticals and submitted a request for an Emergency Use Authorization for Niyad.
Submitted a request for an EUA for Niyad on April 27, 2023.
Closed the divestment of DSUVIA to Alora Pharmaceuticals on April 3, 2023.
Cash and cash equivalents balance was $13.4 million as of March 31, 2023.
Net loss attributable to common shareholders for the first quarter of 2023 was $8.2 million, or $0.75 per basic and diluted share.
AcelRx
AcelRx
Forward Guidance
AcelRx is focused on initiating the FDA-informed single registrational study for Niyad in the second half of this year and has agreed upon terms for the supply of the active pharmaceutical ingredient.